# Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

> **NCT04293887** · EARLY_PHASE1 · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 328 (estimated)

## Conditions studied

- COVID-19
- Recombinant Human Interferon α1β

## Interventions

- **DRUG:** Recombinant human interferon α1β

## Key facts

- **NCT ID:** NCT04293887
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2020-05-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293887, "Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04293887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*